Long-term efficacy and safety of galantamine in outpatients with mild cognitive disorder by Zarra, Julio & Schmidt, Luisa
MEETING ABSTRACT Open Access
Long-term efficacy and safety of galantamine
in outpatients with mild cognitive disorder
Julio Zarra
1*, Luisa Schmidt
2
From 1
st International Congress on Neurobiology and Clinical Psychopharmacology and European
Psychiatric Association Conference on Treatment Guidance
Thessaloniki, Greece. 19-22 November 2009
Background
Galantamine is a reversible, competitive cholinesterasa
inhibitor that also allosterically modulates nicotine
acetylcholine receptors. Inhibition of acetylcholinester-
ase, the enzyme responsible for hydrolisis of acetylcho-
line at the cholinergic cognitive impairment. To evaluate
the efficacy, safety and tolerability of galantamine in
long-term in Mild Cognitive Disorder.
Materials and methods
A multicenter, open label, prospective, observational
study enrolled 800 patients, more 50 years old with
Mild Neurocognitive Disorder (DSM IV criteria), during
24 months of treatment with galantamine 16 mg./day.
Assessments included the Mini Mental State Examina-
tion (MMSE), Clinical Dementia Rating (CDR), Alzhei-
mer’s Disease Assessment Scale (ADAS-GOG), Seven
minutes test, Wiscosin card sorting test, Boston naming
test, Token test, Raven Test, Brow-Peterson test, Trail
making test, Functional Activities Questionnaire (FAQ),
GO-NO-GO test, Global Deterioration Scale, Global
Clinical Impression (GCI) and UKU scale of Adverse
Effects.
Results
A total 800 outpatients were treated with 16 mg./day
galantamine during 24 months, the therapeutic response
evaluated with CDR, MMSE and the tests and scales of
function cognitive measuring, GCI and UKU scale of
adverse effects, comparing the baseline to final scores.
Conclusions
Mild Cognitive Disorder is being examined, so there
aren’t enought treatment for this. A long-term treatment
(24 months) galantamine improves cognition and global
function, behavioural symptoms and the general state
well being of patients with Mild cognitive Disorder.
With incidence of adverse effects not significant and a
very good profile of safety, the final results of the study
suggest that galantamine may be particularly appropiate
in the Mild Cognitive Disorder.
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